We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+24.81%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$672M
AUM Growth
+$62.1M
Cap. Flow
+$17.3M
Cap. Flow %
2.57%
Top 10 Hldgs %
63.33%
Holding
37
New
10
Increased
13
Reduced
3
Closed
10

Top Buys

Rank Stock Value
1
MYGN icon
Myriad Genetics
MYGN
+$54M
2
MASI
Masimo
MASI
+$27.2M
3
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$16.9M
4
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$16.9M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$16M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$45.3M
2
CSII
Cardiovascular Systems, Inc.
CSII
+$37.5M
3
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$30.1M
4
MDCO
Medicines Co
MDCO
+$25.5M
5
EBS icon
Emergent Biosolutions
EBS
+$25.1M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.2B
$63M 9.37%
669,690
+91,000
+16% +$9.31M
MYGN icon
2
Myriad Genetics
MYGN
$507M
$59.6M 8.87%
+1,744,150
New +$54M
FURX
3
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$53.6M 7.98%
616,495
-32,334
-5% -$2.5M
ENTA icon
4
Enanta Pharmaceuticals
ENTA
$378M
$50.2M 7.46%
1,254,459
+403,165
+47% +$14.6M
OPCH icon
5
Option Care Health
OPCH
$3.36B
$35.1M 5.22%
1,255,693
+275,360
+28% +$8.5M
AEGR
6
DELISTED
Aegerion Pharmaceuticals
AEGR
$35M 5.21%
758,970
+221,936
+41% +$13M
INSY
7
DELISTED
Insys Therapeutics, Inc.
INSY
$33.2M 4.95%
1,604,774
-488,515
-23% -$9.69M
OFIX icon
8
Orthofix Medical
OFIX
$477M
$33.1M 4.93%
1,098,670
+167,618
+18% +$3.86M
ANAC
9
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$32.2M 4.79%
1,610,467
+240,587
+18% +$4.66M
TARO
10
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$30.6M 4.55%
275,232
+11,500
+4% +$1.25M
MASI
11
DELISTED
Masimo
MASI
$29.7M 4.43%
1,089,034
+952,159
+696% +$27.2M
OSIR
12
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$27M 4.01%
2,055,024
+1,079,008
+111% +$16.9M
HPTX
13
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$26.5M 3.94%
1,026,092
+291,796
+40% +$7.91M
VNDA icon
14
Vanda Pharmaceuticals
VNDA
$312M
$19.9M 2.97%
1,226,772
+1,122,772
+1,080% +$16M
ISRG icon
15
Intuitive Surgical
ISRG
$126B
$16M 2.38%
+329,400
New +$15.5M
WX
16
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$15.9M 2.36%
430,889
-821,425
-66% -$30.1M
INFI
17
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$15M 2.23%
+1,262,012
New +$16.9M
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$14M 2.09%
+1,047,576
New +$11.2M
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$13.9M 2.07%
200,600
+58,300
+41% +$4.28M
RXII
20
DELISTED
GALENA BIOPHARMA INC COM
RXII
$13.6M 2.03%
5,446,469
+2,459,523
+82% +$6.15M
DSCI
21
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$11.3M 1.68%
+891,555
New +$11.5M
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$11.1M 1.65%
+311,287
New +$10.5M
TVTY
23
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$10.2M 1.52%
+594,098
New +$9.14M
ANIP icon
24
ANI Pharmaceuticals
ANIP
$1.83B
$7.88M 1.17%
+251,263
New +$6.67M
PTX
25
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$6.51M 0.97%
+121,720
New +$4.02M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, Consonance Capital Management held 37 positions worth $672M, up 10% from $610M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Consonance Capital Management's Q1 2014 filing shows 10 new, 13 increased, 3 reduced and 10 closed positions. Its largest new stake was Myriad Genetics: 1,744,150 shares worth $59.6M. The largest sale was Endo International plc, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 62% a quarter earlier.

  • Consonance Capital Management's largest Q1 2014 buy was Myriad Genetics: 1,744,150 shares worth $59.6M.
  • Consonance Capital Management added most to Masimo in Q1 2014, an estimated $27.2M increase.
  • Consonance Capital Management's biggest Q1 2014 reduction was WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS, cutting an estimated $30.1M.
  • Consonance Capital Management fully exited Endo International plc in Q1 2014, selling an estimated $45.3M.
  • Consonance Capital Management's ten largest holdings make up 63% of its $672M portfolio in Q1 2014.
  • Consonance Capital Management opened 10 new positions and closed 10 in Q1 2014.
  • Consonance Capital Management's portfolio value rose 10% quarter-over-quarter to $672M.

Based on Consonance Capital Management's 13F filing for Q1 2014, filed 15 May 2014.